Medifast 5 & 1 Plan
Primary Purpose
Obesity, Body Weight, Weight Loss
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Food-based, Reduced Energy Diet Plan
Medifast 5 & 1 Plan
Sponsored by
About this trial
This is an interventional treatment trial for Obesity focused on measuring obesity, overweight, weight loss, randomized controlled trial, Medifast
Eligibility Criteria
Inclusion Criteria:
- BMI 35-50 kg/m2
- Interested in weight loss
- Computer with internet access
- Any race or ethnicity
- Fasting glucose <126 mg/dL at screening
Exclusion Criteria:
- Participation in any weight-reduction program, weight-loss diet, or other special diet within the previous 3 months.
- Weight loss or gain of >5% body weight in past 6 months for any reason except post-partum weight loss.
- Currently taking any medication that suppresses or stimulates appetite.
- History of prior surgical procedure for weight control or liposuction.
- Current smoker or quit smoking less than 6 months prior.
Any major disease, including:
- Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).
- Active or chronic infections, including self-reported HIV positivity and active tuberculosis.
- Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease (e.g., coronary artery bypass, percutaneous transluminal coronary angioplasty) in the past 6 months; New York Heart Association Functional Class >2 with respect to congestive heart failure; stroke or transient ischemic attack in the past 6 months.
- Uncontrolled hypertension: systolic blood pressure >160 mm Hg or diastolic blood pressure >95 mm Hg on treatment.
- Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
- Active kidney disease.
- Lung disease: chronic obstructive airway disease requiring use of oxygen.
- Diagnosed diabetes (type 1 or 2), fasting hyperglycemia (blood glucose >126 mg/dL), or use of any anti-diabetic medications.
- Uncompensated or uncontrolled psychiatric disease (such as schizophrenia and bipolar disorder) that, in opinion of the investigators, would impede conduct of the trial or completion of procedures.
- A score on the Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983) that exceeds the 90th percentile.
- History of or current eating disorders, or an Eating Attitudes Test (EAT 40) score >30.
- Active food allergies, particularly to wheat, gluten, soy or nuts.
- Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; another household member is a participant or staff member in the trial; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes.
- Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable.
- No regular source of health care.
- Any active use of illegal or illicit drugs or history of illegal or illicit drug utilization within past year
- Excessive alcohol intake, either acute or chronic defined as any one of the following: 1) average consumption of 3 or more alcohol containing beverages daily; 2) consumption of 7 or more alcoholic beverages within a 24-hr period in the past 12 months; or 3) other evidence available to clinic staff.
- Willing to limit alcohol intake to zero
- Pregnancy and childbearing: currently pregnant or less than 3 months post partum; currently nursing or within 6 weeks of having completed nursing; pregnancy anticipated during study; unwilling to report possible or confirmed pregnancies promptly during the course of the trial; unwilling to take adequate contraceptive measures if potentially fertile.
- Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Sites / Locations
- University of Alabama at Birmingham Division of Preventive Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Food-based, Reduced Energy Diet Plan
Medifast 5 & 1 Plan
Arm Description
Outcomes
Primary Outcome Measures
Body weight
Secondary Outcome Measures
Waist circumference
Body composition as measured by bioelectrical impedence (BIA)
Body mass index
Low-density lipoprotein cholesterol (LDL)
High-density lipoprotein cholesterol (HDL)
Triglycerides
Glucose
Liver function tests
High-sensitivity C-reactive protein (hs-CRP)
Lipid hydroperoxides
Blood pressure
Appetite/satiety measures
Full Information
NCT ID
NCT01211301
First Posted
September 28, 2010
Last Updated
June 17, 2013
Sponsor
University of Alabama at Birmingham
Collaborators
Medifast, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01211301
Brief Title
Medifast 5 & 1 Plan
Official Title
Randomized Controlled Trial of the Medifast 5 & 1 Plan
Study Type
Interventional
2. Study Status
Record Verification Date
June 2013
Overall Recruitment Status
Completed
Study Start Date
October 2010 (undefined)
Primary Completion Date
February 2012 (Actual)
Study Completion Date
April 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
Collaborators
Medifast, Inc.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the effectiveness of the Medifast 5 & 1 Plan to a food-based, reduced-energy diet plan. The study will be conducted over 52 weeks, including a 26-week weight-loss phase and a 26-week weight-maintenance phase. 120 participants will be enrolled, with 60 randomized to the Medifast 5 & 1 Plan and 60 randomized to food-based, reduced-energy diet plan. Multiple measures will be performed at baseline, 26 weeks, and 52 weeks, including anthropometry, body composition, blood pressure, blood assays, and appetite sensations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Body Weight, Weight Loss, Overweight, Nutrition Disorders
Keywords
obesity, overweight, weight loss, randomized controlled trial, Medifast
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Food-based, Reduced Energy Diet Plan
Arm Type
Active Comparator
Arm Title
Medifast 5 & 1 Plan
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Food-based, Reduced Energy Diet Plan
Intervention Description
Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
Intervention Type
Other
Intervention Name(s)
Medifast 5 & 1 Plan
Intervention Description
Participants randomized to the Medifast group will enroll online in the Medifast 5 & 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean & Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 & 1 Plan. The Medifast 5 & 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean & Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 & 1 Plan.
Primary Outcome Measure Information:
Title
Body weight
Time Frame
26 and 52 weeks
Secondary Outcome Measure Information:
Title
Waist circumference
Time Frame
26 and 52 weeks
Title
Body composition as measured by bioelectrical impedence (BIA)
Time Frame
26 and 52 weeks
Title
Body mass index
Time Frame
26 and 52 weeks
Title
Low-density lipoprotein cholesterol (LDL)
Time Frame
26 and 52 weeks
Title
High-density lipoprotein cholesterol (HDL)
Time Frame
26 and 52 weeks
Title
Triglycerides
Time Frame
26 and 52 weeks
Title
Glucose
Time Frame
26 and 52 weeks
Title
Liver function tests
Time Frame
26 and 52 weeks
Title
High-sensitivity C-reactive protein (hs-CRP)
Time Frame
26 and 52 weeks
Title
Lipid hydroperoxides
Time Frame
26 and 52 weeks
Title
Blood pressure
Time Frame
26 and 52 weeks
Title
Appetite/satiety measures
Time Frame
26 and 52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
BMI 35-50 kg/m2
Interested in weight loss
Computer with internet access
Any race or ethnicity
Fasting glucose <126 mg/dL at screening
Exclusion Criteria:
Participation in any weight-reduction program, weight-loss diet, or other special diet within the previous 3 months.
Weight loss or gain of >5% body weight in past 6 months for any reason except post-partum weight loss.
Currently taking any medication that suppresses or stimulates appetite.
History of prior surgical procedure for weight control or liposuction.
Current smoker or quit smoking less than 6 months prior.
Any major disease, including:
Active cancer or cancer requiring treatment in the past 2 years (except nonmelanoma skin cancer).
Active or chronic infections, including self-reported HIV positivity and active tuberculosis.
Active cardiovascular disease or event including hospitalization or therapeutic procedures for treatment of heart disease (e.g., coronary artery bypass, percutaneous transluminal coronary angioplasty) in the past 6 months; New York Heart Association Functional Class >2 with respect to congestive heart failure; stroke or transient ischemic attack in the past 6 months.
Uncontrolled hypertension: systolic blood pressure >160 mm Hg or diastolic blood pressure >95 mm Hg on treatment.
Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
Active kidney disease.
Lung disease: chronic obstructive airway disease requiring use of oxygen.
Diagnosed diabetes (type 1 or 2), fasting hyperglycemia (blood glucose >126 mg/dL), or use of any anti-diabetic medications.
Uncompensated or uncontrolled psychiatric disease (such as schizophrenia and bipolar disorder) that, in opinion of the investigators, would impede conduct of the trial or completion of procedures.
A score on the Brief Symptom Inventory (BSI) (Derogatis & Melisaratos, 1983) that exceeds the 90th percentile.
History of or current eating disorders, or an Eating Attitudes Test (EAT 40) score >30.
Active food allergies, particularly to wheat, gluten, soy or nuts.
Conditions or behaviors likely to effect the conduct of the trial: unable or unwilling to give informed consent; unable to communicate with the pertinent clinic staff; another household member is a participant or staff member in the trial; unwilling to accept treatment assignment by randomization; current or anticipated participation in another intervention research project that would interfere with the intervention offered in the trial; likely to move away from participating clinics before trial completed; unable to walk 0.25 mile in 10 minutes.
Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable.
No regular source of health care.
Any active use of illegal or illicit drugs or history of illegal or illicit drug utilization within past year
Excessive alcohol intake, either acute or chronic defined as any one of the following: 1) average consumption of 3 or more alcohol containing beverages daily; 2) consumption of 7 or more alcoholic beverages within a 24-hr period in the past 12 months; or 3) other evidence available to clinic staff.
Willing to limit alcohol intake to zero
Pregnancy and childbearing: currently pregnant or less than 3 months post partum; currently nursing or within 6 weeks of having completed nursing; pregnancy anticipated during study; unwilling to report possible or confirmed pregnancies promptly during the course of the trial; unwilling to take adequate contraceptive measures if potentially fertile.
Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David B. Allison, PhD.
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
James M. Shikany, DrPH
Organizational Affiliation
University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Alabama at Birmingham Division of Preventive Medicine
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35205
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23567927
Citation
Shikany JM, Thomas AS, Beasley TM, Lewis CE, Allison DB. Randomized controlled trial of the Medifast 5 & 1 Plan for weight loss. Int J Obes (Lond). 2013 Dec;37(12):1571-8. doi: 10.1038/ijo.2013.43. Epub 2013 Apr 9.
Results Reference
result
Learn more about this trial
Medifast 5 & 1 Plan
We'll reach out to this number within 24 hrs